Resilience in the Face of Lung Cancer: A Young Mother’s Story of Hope
(BPT) - At 37, Lexi never imagined cancer would become part of her story, especially as a vibrant, active mom of three. Diagnosed with metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) exon 20 insertion mutation, she shares how she navigated her diagnosis, working closely with her care team to integrate RYBREVANT® into her treatment plan.
By taking proactive steps to address potential side effects before starting RYBREVANT®, Lexi established a routine that helps her fit her treatment into her daily life and feel more confident in her care.
"I think that it's a huge win to be able to take this drug, have access to this effective treatment. You don't want to wait for these symptoms to come to try to combat them."
Lexi emphasizes the power of informed decision-making, from staying current on treatment breakthroughs to tuning into your body's signals and leaning on loved ones for support.
"It's okay to have moments where you're not strong and where it's acknowledging how hard it is. You got to get up. You got to find the things that make you happy and do those things and push through."
Please read the Important Safety Information below. To learn more, talk to your doctor or visit rybrevant.com.
Lexi is a real patient and a volunteer with the SHARE Network, a Johnson & Johnson program made up of people who are dedicated to inspiring others through their personal health journeys and stories of caring. Every patient's experience is unique, and Lexi's journey is not representative of all patients. Lexi has been compensated for her time.
What is RYBREVANT® (amivantamab-vmjw)?
RYBREVANT® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal epidermal growth factor receptor (EGFR) gene(s):
- in combination with LAZCLUZE® (lazertinib), a prescription medicine, as a first-line treatment for non-small cell lung cancer (NSCLC)
- in combination with carboplatin and pemetrexed as a second-line treatment for NSCLC in patients whose disease has worsened on or after treatment with an EGFR tyrosine kinase inhibitor (TKI)
- in combination with carboplatin and pemetrexed as a first-line treatment for NSCLC
- alone for the treatment of NSCLC whose disease has worsened on or after platinum-based chemotherapy.
Your healthcare provider will perform a test to make sure that RYBREVANT® or RYBREVANT® in combination with LAZCLUZE® is right for you.
It is not known if RYBREVANT® or LAZCLUZE® is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Before you receive RYBREVANT® as a single agent or in combination, tell your healthcare provider about all of your medical conditions, including if you:
- have a history of lung or breathing problems.
- are pregnant or plan to become pregnant. RYBREVANT® and LAZCLUZE® can harm your unborn baby.
Females who are able to become pregnant:
- Your healthcare provider should do a pregnancy test before you start treatment with RYBREVANT® or RYBREVANT® in combination with LAZCLUZE®.
- You should use effective birth control (contraception) during treatment and for 3 months after your final dose of RYBREVANT®.
- For patients receiving LAZCLUZE®: You should use effective birth control (contraception) during treatment and for 3 weeks after your last dose of LAZCLUZE®.
- Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with RYBREVANT® or LAZCLUZE®.
Males who have female partners who are able to become pregnant:
- You should use effective birth control during treatment and for 3 weeks after your last dose of LAZCLUZE®.
- are breastfeeding or plan to breastfeed. It is not known if RYBREVANT® or LAZCLUZE® passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of RYBREVANT® or RYBREVANT® in combination with LAZCLUZE®.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
LAZCLUZE® may affect the way other medicines work, and other medicines may affect how LAZCLUZE® works. You should not start or stop any medicine before you talk with your healthcare provider that prescribed LAZCLUZE®.
What should I avoid while receiving RYBREVANT® and/or LAZCLUZE®?
RYBREVANT® and RYBREVANT® in combination with LAZCLUZE® can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment with RYBREVANT® and/or LAZCLUZE®. Wear protective clothing and use broad-spectrum UVA/UVB sunscreen during treatment with RYBREVANT® and/or LAZCLUZE®.
What are the possible side effects of RYBREVANT® and/or LAZCLUZE®?
RYBREVANT® and/or LAZCLUZE® may cause serious side effects, including:
- infusion-related reactions. Infusion-related reactions are common with RYBREVANT® but can be severe or serious and can include life-threatening (anaphylaxis) allergic reaction. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of RYBREVANT®:
|
|
- lung problems. RYBREVANT® and LAZCLUZE® may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.
- blood clot problems. Blood clots are a serious, but common side effect of RYBREVANT®, when given together with LAZCLUZE®, may cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Your healthcare provider will start you on medicine to reduce the risk of blood clots for the first 4 months of treatment. Tell your healthcare provider right away if you have any signs and symptoms of blood clots, including swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
- skin problems. RYBREVANT® and LAZCLUZE® can cause severe rash, including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may start you on an antibiotic for the first 3 months of treatment followed by an antibiotic lotion for your scalp for the next 9 months. During treatment, you should apply a non-comedogenic (does not clog pores) skin moisturizer (ceramide based or other types of moisturizers that provide long lasting skin hydration and does not include drying ingredients) on your face and whole body (except scalp) and wash your hands and feet every day with 4% chlorhexidine solution. Your healthcare provider may treat you with a medicine(s) or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with RYBREVANT® or LAZCLUZE®. See "What should I avoid while receiving RYBREVANT® and/or LAZCLUZE®?"
- eye problems. RYBREVANT® and LAZCLUZE®may cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems which may include:
|
|
Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with RYBREVANT® or LAZCLUZE®. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.
The most common side effects of RYBREVANT® in combination with LAZCLUZE® include:
|
|
LAZCLUZE® may cause fertility problems in males and females, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.
The most common side effects of RYBREVANT® when given in combination with carboplatin and pemetrexed include:
|
|
The most common side effects of RYBREVANT® when given alone:
|
|
Your healthcare provider may temporarily stop, decrease your dose, or completely stop your treatment with RYBREVANT® or LAZCLUZE® if you have serious side effects.
These are not all the possible side effects of RYBREVANT® or LAZCLUZE®.
Call your doctor for medical advice about side effects. You may report side effects to FDA at
1-800-FDA-1088.
General information about the safe and effective use of RYBREVANT® or LAZCLUZE®:
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use medications for a condition for which it was not prescribed or give to other people, even if they have the same symptoms that you have. It may harm them.
Please read full Prescribing Information forRYBREVANT® andLAZCLUZE®.
cp-213277v9
Source: BrandPoint
